PrefaceKinase Inhibitors in the Treatment of Myeloid Malignancies
References (0)
Cited by (1)
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
2019, BloodCitation Excerpt :We observed that EZH2 and SRSF2 mutations had higher VAFs in CNL/aCML/unclassifiable/CMML compared with AML (supplemental Figure 3B). In addition, a trend of increased VAFs of the signaling gene (NRAS, PTPN11, and NF1) mutations was observed in our cohort compared with the VAFs of signaling gene mutations in AML (supplemental Figure 3B),17,29 indicating that these signaling mutations may contribute to the unique phenotype of CNL/aCML/unclassifiable/CMML and may represent important pharmaceutical targets.30 Since we observed multiple pairs of coexisting mutations (Figure 2B), we next determined the order of acquisition of these events and whether they were predicted to exist within the same tumor clones.
© 2017 Published by Elsevier Inc.